ARA-290
Also known as Cibinetide, Helix B surface peptide
An erythropoietin-derived peptide studied for tissue-protective and anti-inflammatory signaling without the red-blood-cell stimulation associated with EPO.
Overview
ARA-290, also called cibinetide, is a peptide derived from the tissue-protective region of erythropoietin biology. It is designed to avoid EPO's red-blood-cell-stimulating effects.
The Science
The research focus is tissue protection and inflammation modulation rather than erythropoiesis.
- Innate repair receptor signaling - proposed tissue-protective pathway.
- Neuropathy research - studied in small-fiber neuropathy and pain-related contexts.
- Inflammation resolution - interest in immune and vascular repair signaling.
Evidence Snapshot
ARA-290 has human research history but remains investigational. It should not be confused with EPO or interpreted as a red-blood-cell boosting compound.
Related
More in Healing & Recovery
Botulinum Toxin
FDA-approvedHealing & Recovery
Not a peptideProtein toxin
A bacterial neurotoxin protein used clinically in tightly controlled doses for neuromuscular, migraine, autonomic, and cosmetic indications; it is not a peptide supplement.
BPC-157
Research compoundHealing & Recovery
A stable 15-amino-acid peptide fragment derived from a protein in human gastric juice, widely studied in preclinical models for tissue protection and repair across gut, tendon, muscle, and vascular tissue.
Cartalax
Research compoundHealing & Recovery
A bioregulator peptide product discussed in cartilage, joint, and connective-tissue aging contexts, with evidence best treated as preliminary and formulation-dependent.